Interstitial Lung Disease Clinical Trials 2023

What are the top hospitals conducting interstitial lung disease research?

Interstitial lung disease (ILD) is a complex and often debilitating condition that affects the lungs, making it difficult for individuals to breathe properly. Fortunately, there are several top hospitals at the forefront of clinical trials dedicated to finding innovative treatments and improving outcomes for patients with ILD. In Rochester, Minnesota, Mayo Clinic leads the way with four current active ILD trials and an impressive track record of four completed studies since their first recorded trial in 2021.

Heading westward to Kansas City, the University of Kansas Medical Center is also making significant contributions in the field of ILD research. With three ongoing trials and nine historical ones dating back to their initial investigation in 2016, this institution showcases its commitment to advancing knowledge about this challenging lung condition.

Meanwhile, on the picturesque shores of Seattle sits Harborview Medical Center - a hospital renowned for its expertise in interstitial lung disease. Despite having two currently active clinical trials related to ILD, they have made substantial progress through four previous studies initiated in 2016.

At Southeastern Research Center located in Winston-Salem focuses on investigating new treatment options for those suffering from interstitial lung disease as well. Their dedication can be seen through their participation in two active clinical trials while contributing another four previous experiments since starting their investigations back yet only recently into 2017.

Lastly but not least Vanderbilt University Medical Center stands out among these prestigious institutions as well by joining forces against ILD with two ongoing clinical trials and six prior investigations conducted since recording their earliest trial over ten years ago during2009

These prominent hospitals across different regions represent beacons of hope for patients battling with interstitial lung disease who yearn for improved therapies or even cures. By pushing boundaries through comprehensive research efforts and innovative clinical trials focused solely on tackling this chronic respiratory ailment head-on; these medical experts are paving new paths towards better understanding causes risks diagnosis & ultimately more effective treatments that carry potential transforming countless lives worldwide

Which are the best cities for interstitial lung disease clinical trials?

When it comes to interstitial lung disease clinical trials, several cities stand out as hubs for research and medical advancements. Los Angeles, California boasts 8 active trials studying treatments like MK-2225, 68Ga-FAPi-46, and Nintedanib (Ofev®). Seattle, Washington follows closely behind with 7 ongoing studies focused on interventions such as the Jumpstart Guide and BI 1015550 low dose. New york, New York also has 7 active trials exploring treatment options like Nintedanib plus Standard of Care and BI 1015550 low dose. In Rochester, Minnesota and Boston, Massachusetts there are both 6 active trials investigating various therapies including Amitriptyline 50 MG and Nintedanib plus Standard of Care. These cities offer individuals with interstitial lung disease opportunities to participate in cutting-edge clinical trials that may lead to breakthroughs in treatment approaches.

Which are the top treatments for interstitial lung disease being explored in clinical trials?

Exciting advancements are taking place in the field of interstitial lung disease (ILD), with several top treatments showing promise in clinical trials. Topping the list is abatacept, currently being explored in two active trials dedicated to ILD. Since its first listing in 2017, it has been involved in a total of three ILD trials, positioning itself as a potential game-changer for patients. Another notable contender is nintedanib, also participating in two ongoing ILD studies and boasting a track record of 12 all-time clinical trials since 2017. Lastly, there's the Jumpstart Guide—a newcomer on the scene—currently undergoing one active trial for ILD after its recent introduction in 2023. These innovative treatments offer hope for those affected by this challenging respiratory condition and represent significant progress towards finding effective therapies for ILD management.

What are the most recent clinical trials for interstitial lung disease?

Recent clinical trials offer promising prospects for individuals with interstitial lung disease, a condition that affects the lungs' ability to function properly. One significant trial involves efzofitimod, which aims to evaluate its efficacy in treating this disease. Another study explores the potential benefits of mycophenolate mofetil as a treatment option. Additionally, researchers are investigating the effectiveness of nintedanib when combined with standard care for managing interstitial lung disease. In parallel, vixarelimab has shown potential during phase 2 trials involving patients with this condition. Lastly, the use of fisetin is being investigated through another phase 2 trial focusing on interstitial lung disease management strategies. These ongoing studies hold promise in advancing our understanding and improving treatments for individuals living with this challenging respiratory disorder.

What interstitial lung disease clinical trials were recently completed?

Several notable clinical trials focusing on interstitial lung disease have recently reached completion, marking significant progress in the search for improved treatments. In November 2019, Mayo Clinic successfully completed a trial investigating the potential of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs). Similarly, Boehringer Ingelheim concluded their study on Nintedanib in April 2019 and another trial with the same medication back in November 2017. Additionally, Michael Roth sponsored a Pirfenidone (PFD) trial that wrapped up in November 2017. These advancements signify the tireless efforts of researchers to address this challenging condition and bring hope to those affected by interstitial lung disease.